We are pleased to announce that WuXi NextCODE has successfully completed a $240 million Series B financing. The company extended and completed the Series B round with investment from a consortium led by Sequoia China, and including Temasek, Yunfeng Capital and 3W Partners.

WuXi NextCODE is using the proceeds from this round to accelerate the extension of its platform infrastructure and to bring new users and data onboard through precision medicine and diagnostics partnerships; the commercialization of its consumer solutions for the China market; and ultimately by enabling individuals to take charge of their own genomic data and deploy it to advance health and healthcare.

The company plans  to continue to push the leading edge of technology for digitizing, managing and analyzing genomic big data, including through its pathbreaking AI, and to provide those services to more enterprises, institutions, and individuals around the world.

Related Links:

Official Press Release

WuXi NextCODE AI Points to New Therapeutic Approaches to Cardiovascular Disease and Cancer in Yale Nature Study